Upper Tract Urothelial Carcinoma

Population Genomic Screening for 3 Conditions Likely Cost-Effective

Publish Date May 11, 2023

Genomic screening for Lynch syndrome, hereditary breast and ovarian cancer syndrome, and familial hypercholesterolemia likely cost-effective for adults younger than 40 years

AUA, SUO Issue New Guideline on Nonmetastatic UTUC

Publish Date May 9, 2023

The new guideline aims to limit toxicity and improve cancer control and survival in patients with UTUC.

UTUC Recurrence After Endoscopic Treatment ID’d as Only Mortality Predictor

Publish Date May 1, 2023

Findings are based on a study of 215 patients who underwent 392 endoscopic procedures for upper tract urothelial carcinoma.

Neoadjuvant Chemotherapy Beneficial in High-Risk UTUC

Publish Date March 3, 2023

Findings of a phase 2 trial support the use of neoadjuvant chemotherapy as a standard of care, according to investigators.

Neoadjuvant Chemo Predicts Better Survival in Node Positive UTUC

Publish Date February 21, 2023

Receipt of neoadjuvant vs adjuvant chemotherapy did not differ significantly by clinical nodal stage.

UGN-101 Reviewed in Real-World Upper Tract Urothelial Cancer Setting

Publish Date January 31, 2023

For patients with low-grade residual disease, complete response rate was 70% with UGN-101

Estimating Post-Nephrectomy GFR May Guide Treatment Decisions

Publish Date August 24, 2022

An accurate estimate of future GFR after nephrectomy would help to guide operative strategy and use of adjuvant or neoadjuvant therapies, according to a recent editorial.

UTUC Adjuvant Chemotherapy Beneficial in Selected Cases

Publish Date July 8, 2022

Adjuvant chemotherapy prolongs survival among patients with negative surgical margins regardless of number of positive lymph nodes.

Predictors of Recurrence After RNU for Low-Grade UTUC

Publish Date May 15, 2022

Findings may inform surveillance strategies and improve treatment outcomes.

UTUC in Octogenarians Frequently Managed Without Surgery

Publish Date May 15, 2022

Approximately one-quarter of patients aged 80 years or older with upper tract urothelial carcinoma are managed expectantly, data show.